Volume 25, Issue 4, Pages 327-333 (December 2018) Potential use of bitter melon (Momordica charantia) derived compounds as antidiabetics: In silico and in vivo studies  Olusola Olalekan Elekofehinti, Esther Opeyemi Ariyo, Moses Orimoloye Akinjiyan, Olanrewaju Sam Olayeriju, Akeem Olalekan Lawal, Isaac Gbadura Adanlawo, Joao Batista Teixeira Rocha  Pathophysiology  Volume 25, Issue 4, Pages 327-333 (December 2018) DOI: 10.1016/j.pathophys.2018.05.003 Copyright © 2018 Elsevier B.V. Terms and Conditions

Fig. 1 Qualitative-PCR analysis of GLP-1 expression in M. charantia fed rats (n = 5) for 72 h. Snapshot represention of RT-PCR and chain reaction-agarose gel electrophoresis was carried on GLP-1 gene followed by desitometric analysis. Pathophysiology 2018 25, 327-333DOI: (10.1016/j.pathophys.2018.05.003) Copyright © 2018 Elsevier B.V. Terms and Conditions

Fig. 2 Qualitative-PCR analysis of DPP-4 expression in M. charantia fed rats (n = 5) for 72 h. Snapshot represention of RT-PCR and chain reaction-agarose gel electrophoresis was carried on DPP-4 gene followed by desitometric analysis. Pathophysiology 2018 25, 327-333DOI: (10.1016/j.pathophys.2018.05.003) Copyright © 2018 Elsevier B.V. Terms and Conditions

Fig. 3 Phytocompounds derived from M. charantia. Pathophysiology 2018 25, 327-333DOI: (10.1016/j.pathophys.2018.05.003) Copyright © 2018 Elsevier B.V. Terms and Conditions

Fig. 4 Binding pose of phytocompounds (sphere representation) derived from M. charantia into the active site of (a)DPP4, (b) GLP-1 and (c) TGR5. Pathophysiology 2018 25, 327-333DOI: (10.1016/j.pathophys.2018.05.003) Copyright © 2018 Elsevier B.V. Terms and Conditions